

In addition to antioxidant protective benefits, Phloretin CF improves the appearance of discoloration, fine lines, and uneven skin tone.
#PHLO GEL FREE#
Phloretin CF features a patented synergistic combination of 2% phloretin, 10% pure vitamin C (l-ascorbic acid), and 0.5% ferulic acid for enhanced protection against atmospheric skin aging – environmental damage and premature signs of aging caused by free radicals from UVA/UVB, infrared radiation (IRA), and ozone pollution (O3). Inability to maintain hemoglobin 1.7, or platelets The toning and relaxing effect of Phlo-Gel contributes to the tendon and. Severe hypersensitivity or allergy to Activase(R), iodinated contrast or planned treatment anticoagulant drug, except for mild-moderate contrast allergies for which steroid pre-treatment can be used. Phlo-Gel is ideal as an adjuvant in the muscle and tendon decongestant treatment.Pulmonary embolism with hemodynamic compromise or other acute illness precluding tolerance of catheter-directed therapy.Circulatory compromise necessitating surgery.Prior established diagnosis of PTS in lower extremities.Known history of heparin-induced thrombocytopenia (HIT).Symptom duration > 14 days for DVT episode in affected leg.


the recent advances in CDT methods which may lower bleeding risk, but which could, inadvertently, cause more endothelial injury in the smaller caliber vessels of pediatric patients TD PLO gel represent a ready-to-use PLO gel (Premium Lecithin Organogel).the proven ability of rt-PA to dissolve venous thrombus in proximal DVT.the reported association between rapid clot lysis and prevention of PTS.the major burden of PTS on pediatric DVT patients and the U.S.
#PHLO GEL TRIAL#
The rationale for performing the PHLO Trial is based upon: The question of whether CDT using rt-PA improves long-term DVT patient outcomes with acceptable risk and cost is currently being studied in the ATTRACT Trial for adults, but has not yet been addressed in the pediatric population. This method of rt-PA delivery, catheter-directed thrombolysis (CDT), is thought to be safer, more effective, and more efficient than previous methods. Rt-PA is delivered directly into venous thrombus using a catheter/device which is embedded within the thrombus by a physician under imaging guidance. Previous studies have shown the ability of rt-PA to lyse venous thrombus in patients with deep vein thrombosis (DVT), and suggest that successful rt-PA mediated thrombolysis can prevent post-thrombotic syndrome (PTS). Rt-PA, the study drug, is a fibrinolytic drug that is indicated for use in acute myocardial infarction, acute ischemic stroke, and acute massive pulmonary embolism in adults.

They have similar uses, but theyre not the same thing.
